US FDA Granted Orphan Drug Designation to Neuren's NNZ-2591 drug

  • Oct 16, 2019 AEDT
  • Team Kalkine

The Federal agency of the United States Department of Health and Human Services, US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren Pharmaceuticals’ (ASX: NEU) NNZ-2591.

  • Neuren’s NNZ-2591 drug is used in the treatment of each of Phelan-McDermid syndrome and Pitt Hopkins syndrome;
  • Orphan Drug designation is a special status that the FDA may grant to a drug to treat a rare disease or condition;
  • Orphan Drug designation qualifies the sponsor of the drug for 7 years of marketing exclusivity, plus 6 months if approved for pediatric use.

By AEST 1:12 PM, NEU’s stock was trading at $2.470, up by 2.917% on previous close.

 

All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK